US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Clinuvel Pharmaceuticals Ltd.

5.95

+0.07001.19%

Post-market: 5.950.00000.00%19:30 EDT

Volume:5K

Turnover:27.69K

Market Cap:300.05M

PE:12.88

High:5.95

Open:5.80

Low:5.80

Close:5.88

52wk High:8.92

52wk Low:5.80

Shares:50.43M

Float Shares:43.88M

Volume Ratio:0.11

T/O Rate:0.01%

Dividend:0.04

Dividend Rate:0.60%

EPS(TTM):0.4621

EPS(LYR):0.4621

ROE:13.21%

ROA:8.94%

PB:1.53

PE(LYR):12.88

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Clinuvel Pharmaceuticals Ltd.

Exchange:

NASDAQ

Establishment Date:

1999

Employees:

16

Office Location:

535 Bourke Street,Level 22,Melbourne,Victoria,Australia

Website:

http://www.clinuvel.com

Zip Code:

3000

Phone:

Fax:

61 3 9660 4999

Introduction:

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. The company was founded in 1987 and is headquartered in Melbourne, Australia.

Directors

Name

Position

Guy van Dievoet

Non-Executive Director

Jeffrey Rosenfeld

Chair of the Board and Non-Executive Director

Karen Agersborg

Non-Executive Director

Matthew Pringle

Non-Executive Director

Pearl Grimes

Non-Executive Director

Susan Smith

Non-Executive Director

Shareholders

Name

Position

Philippe Wolgen

Chief Executive Officer and Managing Director

Lachlan Hay

Chief Operating Officer

Peter Vaughan

Chief Financial Officer

Dennis Wright

Chief Scientific Officer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/stock/CUVL/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"CUVL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CUVL\",,,,,undefined,":{"symbol":"CUVL","market":"US","secType":"STK","nameCN":"Clinuvel Pharmaceuticals Ltd.","latestPrice":5.95,"timestamp":1789156800000,"preClose":5.88,"halted":0,"volume":4683,"hourTrading":{"tag":"盘后","latestPrice":5.95,"preClose":5.95,"latestTime":"19:30 EDT","volume":5,"amount":29.725,"timestamp":1789169404427,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.011904761904761953,"floatShares":43878300,"shares":50427898,"eps":0.462123,"marketStatus":"Market Closed","change":0.07,"latestTime":"09-11 16:00:00 EDT","open":5.8,"high":5.95,"low":5.8,"amount":27686.912211,"amplitude":0.02551,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.462123,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"adrRate":1,"exchange":"NASDAQ","adjPreClose":5.88,"dividendRate":0.006022,"postHourTrading":{"tag":"盘后","latestPrice":5.95,"preClose":5.95,"latestTime":"19:30 EDT","volume":5,"amount":29.725,"timestamp":1789169404427,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.11327353983328466},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CUVL\",,,,,undefined,":{"symbol":"CUVL","floatShares":43878300,"roa":"8.94%","roe":"13.21%","lyrEps":0.462123,"volumeRatio":0.11327353983328466,"shares":50427898,"dividePrice":0.03586,"high":5.95,"amplitude":0.02551,"preClose":5.88,"low":5.8,"week52Low":5.8,"pbRate":"1.53","psRate":"4.45","week52High":8.92,"institutionHeld":0,"latestPrice":5.95,"eps":0.462123,"divideRate":0.006027,"volume":4683,"delay":0,"ttmEps":0.462123,"open":5.8,"prevYearClose":8.48,"prevWeekClose":6.52,"prevMonthClose":5.95,"prevQuarterClose":7.3,"fiveDayClose":6.28,"twentyDayClose":6.725,"sixtyDayClose":6.92,"dividendPayoutRate":0.055654438728341596,"dividendFrequency":"A","dividendGrowthYears":0,"dividendGrowthRate":-0.12779744805932258,"fiveYearAvgDividendRate":0.004014656862745098},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CUVL\",params:#limit:5,,,undefined,":[{"date":"2026-09-08","symbol":"CUVL","amount":0.03582,"announcedDate":"2026-08-27","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-08","defaultRemindTime":1788874200000,"name":"Clinuvel Pharmaceuticals Ltd.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-28","payableDate":"2026-09-08","currency":"USD","dateTimestamp":1788840000000,"payDate":"2026-09-28"},{"date":"2026-08-27","symbol":"CUVL","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787817600000,"name":null,"time":"Pre-MKt","dateTimestamp":1787803200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CUVL\",market:\"US\",,,undefined,":[{"executeDate":"2026-09-08","recordDate":"2026-09-08","paymentDate":"2026-09-28","value":0.03582,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CUVL\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2857,"buy":0.2857,"hold":0.4286,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.2857,"analysts":7,"updateTime":1787976000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CUVL\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CUVL","date":"2026-09-11","current":12.87536,"percent":0.054054,"low":11.909356,"twenty":12.340531,"median":14.761136,"eighty":15.75761,"high":16.876512,"avg":14.404698,"sd":1.501382,"marketCap":290763266.64},"quantilePoints":[{"date":"2026-07-24","current":15.59024,"twenty":15.398074,"median":15.574742,"eighty":15.64603,"marketCap":353645627.74},{"date":"2026-07-31","current":14.040514,"twenty":14.675902,"median":15.311289,"eighty":15.580941,"marketCap":320255681.34},{"date":"2026-08-07","current":14.62941,"twenty":14.316365,"median":14.745639,"eighty":15.481759,"marketCap":334861674.87},{"date":"2026-08-14","current":14.79988,"twenty":14.434144,"median":14.861869,"eighty":15.354681,"marketCap":340007360.21},{"date":"2026-08-21","current":16.148141,"twenty":14.496133,"median":14.978098,"eighty":15.70182,"marketCap":374125095.76},{"date":"2026-08-28","current":12.593289,"twenty":14.434144,"median":15.047836,"eighty":16.017964,"marketCap":307239459.07},{"date":"2026-09-04","current":12.117509,"twenty":14.049812,"median":14.861869,"eighty":15.918781,"marketCap":295738193.85},{"date":"2026-09-11","current":11.95396,"twenty":12.340531,"median":14.761136,"eighty":15.75761,"marketCap":290763266.64}],"updateTime":1789229361422},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":6117181,"yearFounded":1999,"employeeNum":16,"address":"535 Bourke Street,Level 22,Melbourne,Victoria,Australia","zipCode":"3000","officePhone":"61 3 9660 4900","officeFax":"61 3 9660 4999","fiscalYearEnd":"06-30"},"stockCompanyDetail":{"websiteUrl":"http://www.clinuvel.com","stockEarnings":[{"period":"1week","weight":-0.0874},{"period":"1month","weight":-0.1093},{"period":"3month","weight":-0.049},{"period":"6month","weight":-0.1849},{"period":"1year","weight":-0.1736},{"period":"ytd","weight":-0.2983}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":-0.0106},{"period":"3month","weight":0.0304},{"period":"6month","weight":0.154},{"period":"1year","weight":0.1622},{"period":"ytd","weight":0.1208}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. The company was founded in 1987 and is headquartered in Melbourne, Australia.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.016564},{"month":2,"riseRate":0.25,"avgChangeRate":-0.088904},{"month":3,"riseRate":0.375,"avgChangeRate":0.036975},{"month":4,"riseRate":0.625,"avgChangeRate":0.007121},{"month":5,"riseRate":0.555556,"avgChangeRate":0.057074},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.013615},{"month":7,"riseRate":0.555556,"avgChangeRate":0.025547},{"month":8,"riseRate":0.555556,"avgChangeRate":0.019073},{"month":9,"riseRate":0.444444,"avgChangeRate":0.030613},{"month":10,"riseRate":0.5,"avgChangeRate":-0.018995},{"month":11,"riseRate":0.5,"avgChangeRate":-0.022089},{"month":12,"riseRate":0.625,"avgChangeRate":0.039793}],"exchange":"NASDAQ","name":"Clinuvel Pharmaceuticals Ltd.","nameEN":"Clinuvel Pharmaceuticals Ltd.","securityTypeName":"DR","adrRate":"1:1"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"CUVL\",market:\"US\",,,undefined,":{"directors":[{"name":"Guy van Dievoet","position":"Non-Executive Director"},{"name":"Jeffrey Rosenfeld","position":"Chair of the Board and Non-Executive Director"},{"name":"Karen Agersborg","position":"Non-Executive Director"},{"name":"Matthew Pringle","position":"Non-Executive Director"},{"name":"Pearl Grimes","position":"Non-Executive Director"},{"name":"Susan Smith","position":"Non-Executive Director"}],"executives":[{"name":"Philippe Wolgen","position":"Chief Executive Officer and Managing Director"},{"name":"Lachlan Hay","position":"Chief Operating Officer"},{"name":"Peter Vaughan","position":"Chief Financial Officer"},{"name":"Dennis Wright","position":"Chief Scientific Officer"}]}}}